

1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. *N Engl J Med* 2011;364:1844–1854.
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. *Br J Haematol* 2004;127:3–11.
3. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. *Am J Med* 1980;68:486–491.
4. Altman A. Acute tumor lysis syndrome. *Semin Oncol* 2001;28:3–8.
5. Sallan S. Management of acute tumor lysis syndrome. *Semin Oncol* 2001;28:9–12.
6. Fleming DR, Doukas MA. Acute tumor lysis syndrome in hematologic malignancies. *Leuk Lymphoma* 1992;8:315–318.
7. Hande KR, Garow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. *Am J Med* 1993;94:133–139.
8. Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricemia and tumour lysis syndrome in haematological cancer patients. *Support Care Cancer* 2003;11:249–257.
9. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors—a case report and review of the literature. *Cancer Chemother Pharmacol* 2003;51:187–192.
10. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. *Blood* 2007;109:399–404.
11. Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. *Br J Haematol* 2010;149:578–586.
12. Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. *Gene* 1991;109:281–284.
13. Zimm S, Collins JM, Oneill D, et al. Inhibition of first-past metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. *Clin Pharmacol Ther* 1983;34:810–817.
14. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. *J Clin Oncol* 2010;28:4207–4213.
15. Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. *Leukemia* 2003;17:499–514.
16. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. *Blood* 2001;97:2998–3003.
17. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. *Leuk Res* 2005;29:463–465.
18. Hutcherson DA, Gammon DC, Bhatt MS, et al. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. *Pharmacotherapy* 2006;26:242–247.
19. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. *Bone Marrow Transplant* 2006;37:997–1001.
20. Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. *Bone Marrow Transplant* 2011;46:800–805.
21. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatremia in medical cancer patients: epidemiology, aetiology and differential diagnosis. *Support Care Cancer* 2000;8:192–197.
22. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. *N Engl J Med* 2007;356:2064–2072.
23. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. *Am J Med* 2013;126:S1–S42.
24. Sachs J, Fredman B. The hyponatremia of multiple myeloma is true and not pseudohyponatremia. *Med Hypotheses* 2006;67:839–840.
25. Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. *Am J Respir Crit Care Med* 1997;156:1669–1678.
26. Chute JP, Taylor E, Williams J, et al. A metabolic study of patients with lung cancer and hyponatremia of malignancy. *Clin Cancer Res* 2006;12:888–896.
27. Peri A. Clinical review: the use of vaptans in clinical endocrinology. *J Clin Endocrinol Metab* 2013;98:1321–1332.
28. Gargani L, Schmidt PH, Gheorghiane M. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion. *Expert Rev Cardiovasc Ther* 2011;9:1505–1513.
29. Sillos EM, Shenep JL, Burghen GA, et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. *Cancer* 2001;92:2237–2246.
30. Tiefenthaler M, Amberger A, Bacher N, et al. Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells. *Br J Haematol* 2001;114:574–580.
31. van der Beek A, de Meijer PH, Meinders AE. Lactic acidosis: pathophysiology, diagnosis and treatment. *Neth J Med* 2001;58:128–136.
32. Esbrit P. Hypercalcemia of malignancy—new insights into an old syndrome. *Clin Lab* 2001;47:67–71.
33. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. *N Engl J Med* 2005;352:373–379.
34. Benford HL, Frith JC, Auriola S, et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. *Mol Pharmacol* 1999;56:131–140.
35. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. *J Bone Miner Res* 1998;13:581–589.
36. Purohit OP, Radstone CR, Anthony C, et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. *Br J Cancer* 1995;72:1289–1293.
37. Walker P, Watanabe S, Lawlor P, et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. *Ann Oncol* 1997;8:915–916.
38. Vinholes J, Guo CY, Purohit OP, et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. *J Clin Oncol* 1997;15:131–138.
39. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. *Cochrane Database Syst Rev* 2012;5:CD003188.
40. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. *J Clin Oncol* 2001;19:558–567.
41. Walls J, Ratcliffe WA, Howell A, et al. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. *Br J Cancer* 1994;70:169–172.
42. Warrell RP Jr. Gallium nitrate for the treatment of bone metastases. *Cancer* 1997;80:1680–1685.
43. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor- κ B ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. *Cancer* 2001;92:460–470.
44. Cleeland CS, Body JJ, Stopeck A, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. *Cancer* 2013;119:832–838.
45. Fizazi K, Carducci MA, Smith MR, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. *Lancet* 2011;377:813–822.
46. Hu MI, Glezerman I, Lebouleux S, et al. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. *J Natl Cancer Inst* 2013;105:1417–1420.
47. Mungall S, Mathieson P. Hemolytic uremic syndrome in metastatic adenocarcinoma of the prostate. *Am J Kidney Dis* 2002;40:1334–1336.
48. Gordon LI, Kwaan HC. Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. *Semin Hematol* 1997;34:140–147.
49. Sheldon R, Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. *Cancer* 1986;58:1428–1436.
50. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic uremic syndrome. *Am J Kidney Dis* 2002;40:E16.
51. Verburgh CA, Vermeij CG, Zijlman JM, et al. Haemolytic uraemic syndrome following bone marrow transplantation. Case report and review of the literature. *Nephrol Dial Transplant* 1996;11:1332–1337.
52. Martinez MT, Bucher Ch, Stussi G, et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. *Bone Marrow Transplant* 2005;36:993–1000.
53. Snyder HW Jr, Mittelman A, Oral A, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoabsorption of plasma. *Cancer* 1993;71:1882–1892.
54. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. *Ther Apher* 2002;6:320–328.
55. Kaplan AA. Therapeutic apheresis for cancer related hemolytic uremic syndrome. *Ther Apher* 2000;4:201–206.
56. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. *Medicine (Baltimore)* 2012;91:195–205.